- Report
- February 2023
- 120 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- March 2023
- 147 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- August 2022
- 105 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- November 2020
- 225 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Drug Pipelines
- September 2020
- 96 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- October 2023
- 91 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2022
- 78 Pages
Global
From €1901EUR$2,000USD£1,597GBP
Octreotide is a synthetic somatostatin analogue used to treat a variety of gastrointestinal disorders. It is used to reduce the secretion of hormones such as gastrin, secretin, and vasoactive intestinal peptide, which can cause symptoms such as abdominal pain, diarrhea, and flushing. Octreotide is also used to treat acromegaly, a condition caused by excessive growth hormone production. Octreotide is available in both injectable and oral forms, and is often used in combination with other medications.
Octreotide is a widely used drug in the gastrointestinal market, and is often prescribed for the treatment of various gastrointestinal disorders. It is also used to reduce the symptoms of hormone-related conditions such as acromegaly. Octreotide is generally well-tolerated and has few side effects.
Some companies in the Octreotide market include Novartis, Sandoz, and Teva Pharmaceuticals. Show Less Read more